Wire · opportunities
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
The FDA granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor for adults with ESR1-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer, alongside approval of a companion diagnostic test.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it.
◆ ◆ The Wire takeaway
Oncologists now have a new FDA-approved treatment pathway for ESR1-mutated breast cancer, shifting patient management toward targeted therapy that requires companion diagnostic testing. You need to partner with diagnostic providers and update clinical protocols to capture this growing patient segment.
◆ Coverage
4 sources · 4 Sep 2026
◆ Related on Wire
◆ Topics